Anticoagulation in Cerebral Venous Thrombosis with Chronic Kidney Disease Stage 5

Introduction to Anticoagulation Options

The American College of Cardiology recommends that DOACs are generally contraindicated in CKD stage 5 patients with cerebral venous thrombosis, except for apixaban in the United States, based on limited pharmacokinetic data 1, 2, 3

The European Medicines Agency contraindicates dabigatran, rivaroxaban, and edoxaban for CrCl <15 mL/min and dialysis, due to high renal clearance and risk of accumulation 1, 2
The FDA notes limited clinical data for rivaroxaban in CKD stage 5 and does not approve its use in dialysis patients, while apixaban is approved at 5 mg BID for chronic, stable hemodialysis patients in the US 1, 2, 5
Apixaban has the lowest renal clearance (27%) among all DOACs, making it a potential option in CKD stage 5, although its approval is based on pharmacokinetic simulations rather than clinical outcome trials 4, 3

The CHEST guidelines state that individualized decision-making is appropriate in end-stage renal disease and that NOACs should generally not be used, except for apixaban 5 mg BID in US hemodialysis patients with atrial fibrillation 7
The American College of Chest Physicians recommends using well-managed vitamin K antagonist (warfarin) with target time in therapeutic range (TTR) >65-70% for CVT in CKD stage 5 7, 3

Close INR monitoring is essential when using warfarin in CKD stage 5, and patients should be educated to contact healthcare providers during acute illnesses 3, 4
Apixaban 2.5 mg BID may be considered as an off-label alternative in stable US hemodialysis patients, although this is based on extrapolation from AF/VTE data and carries significant uncertainty 5, 3
Concomitant use of antiplatelet therapy should be avoided due to substantially elevated bleeding risk 7, 5

There is a geographic discrepancy between EMA and FDA guidelines, with EMA contraindicating all DOACs in CKD stage 5 and FDA permitting apixaban use in dialysis 1, 2, 3
Available evidence is primarily for atrial fibrillation and VTE, rather than CVT specifically, which may lead to indication mismatch and uncertainty in clinical decision-making 1, 2, 5